Cargando…

Infection and colonization by Stenotrophomonas maltophilia: antimicrobial susceptibility and clinical background of strains isolated at a tertiary care centre in Hungary

BACKGROUND: Stenotrophomonas maltophilia is an important opportunistic, mainly nosocomial pathogen that emerged in the last decades worldwide. Due to its inherent extended antibiotic resistance, therapeutic options are strongly limited. New resistance mechanisms in S. maltophilia make antibiotic the...

Descripción completa

Detalles Bibliográficos
Autores principales: Juhász, Emese, Krizsán, Gergely, Lengyel, György, Grósz, Gábor, Pongrácz, Júlia, Kristóf, Katalin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307884/
https://www.ncbi.nlm.nih.gov/pubmed/25551459
http://dx.doi.org/10.1186/s12941-014-0058-9
_version_ 1782354510790787072
author Juhász, Emese
Krizsán, Gergely
Lengyel, György
Grósz, Gábor
Pongrácz, Júlia
Kristóf, Katalin
author_facet Juhász, Emese
Krizsán, Gergely
Lengyel, György
Grósz, Gábor
Pongrácz, Júlia
Kristóf, Katalin
author_sort Juhász, Emese
collection PubMed
description BACKGROUND: Stenotrophomonas maltophilia is an important opportunistic, mainly nosocomial pathogen that emerged in the last decades worldwide. Due to its inherent extended antibiotic resistance, therapeutic options are strongly limited. New resistance mechanisms in S. maltophilia make antibiotic therapy even more difficult. The aim of our study was to investigate the antimicrobial resistance of S. maltophilia isolates collected in our laboratory and to reveal related clinical background. METHOD: Consecutive non-duplicate S. maltophilia isolates (n = 160) were collected in a three-year period. Conventional methods, automated identification system and MALDI-TOF MS was used for identification, ERIC-PCR for genetic relationship analysis and broth microdilution method to determine the susceptibility for trimethoprim/sulfamethoxazole (SXT), ciprofloxacin, levofloxacin, moxifloxacin, colistin, doxycycline and tigecycline. Clinical final reports were used retrospectively to collect clinical information. RESULTS: ERIC-PCR revealed large heterogeneity. Trimethoprim/sulfamethoxazole, moxifloxacin and levofloxacin were found to be the most effective agents with MIC50/MIC90 0.5/1, 0.25/1, 1/2 mg/l, respectively. Seventy percent of patients with S. maltophilia infection were treated in intensive care units. All-cause mortality rate was 45%. Nearly 70% of the isolates were collected from polymicrobial infections/colonizations. CONCLUSIONS: Trimethoprim/sulfamethoxazole is the most potent antibiotic agent against S. maltophilia. In case of SXT hypersensitivity, intolerance or resistance, fluoroquinolones are alternative therapeutic options. Missing clinical breakpoints, consensus antibiotic susceptibility testing guidelines and clinical trials make the interpretation of antibiotic susceptibility testing results difficult. The indirect pathogenicity of S. maltophilia in polymicrobial infections or colonizations has to be taken into consideration.
format Online
Article
Text
id pubmed-4307884
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43078842015-01-28 Infection and colonization by Stenotrophomonas maltophilia: antimicrobial susceptibility and clinical background of strains isolated at a tertiary care centre in Hungary Juhász, Emese Krizsán, Gergely Lengyel, György Grósz, Gábor Pongrácz, Júlia Kristóf, Katalin Ann Clin Microbiol Antimicrob Research BACKGROUND: Stenotrophomonas maltophilia is an important opportunistic, mainly nosocomial pathogen that emerged in the last decades worldwide. Due to its inherent extended antibiotic resistance, therapeutic options are strongly limited. New resistance mechanisms in S. maltophilia make antibiotic therapy even more difficult. The aim of our study was to investigate the antimicrobial resistance of S. maltophilia isolates collected in our laboratory and to reveal related clinical background. METHOD: Consecutive non-duplicate S. maltophilia isolates (n = 160) were collected in a three-year period. Conventional methods, automated identification system and MALDI-TOF MS was used for identification, ERIC-PCR for genetic relationship analysis and broth microdilution method to determine the susceptibility for trimethoprim/sulfamethoxazole (SXT), ciprofloxacin, levofloxacin, moxifloxacin, colistin, doxycycline and tigecycline. Clinical final reports were used retrospectively to collect clinical information. RESULTS: ERIC-PCR revealed large heterogeneity. Trimethoprim/sulfamethoxazole, moxifloxacin and levofloxacin were found to be the most effective agents with MIC50/MIC90 0.5/1, 0.25/1, 1/2 mg/l, respectively. Seventy percent of patients with S. maltophilia infection were treated in intensive care units. All-cause mortality rate was 45%. Nearly 70% of the isolates were collected from polymicrobial infections/colonizations. CONCLUSIONS: Trimethoprim/sulfamethoxazole is the most potent antibiotic agent against S. maltophilia. In case of SXT hypersensitivity, intolerance or resistance, fluoroquinolones are alternative therapeutic options. Missing clinical breakpoints, consensus antibiotic susceptibility testing guidelines and clinical trials make the interpretation of antibiotic susceptibility testing results difficult. The indirect pathogenicity of S. maltophilia in polymicrobial infections or colonizations has to be taken into consideration. BioMed Central 2014-12-31 /pmc/articles/PMC4307884/ /pubmed/25551459 http://dx.doi.org/10.1186/s12941-014-0058-9 Text en © Juhász et al.; licensee BioMed Central. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Juhász, Emese
Krizsán, Gergely
Lengyel, György
Grósz, Gábor
Pongrácz, Júlia
Kristóf, Katalin
Infection and colonization by Stenotrophomonas maltophilia: antimicrobial susceptibility and clinical background of strains isolated at a tertiary care centre in Hungary
title Infection and colonization by Stenotrophomonas maltophilia: antimicrobial susceptibility and clinical background of strains isolated at a tertiary care centre in Hungary
title_full Infection and colonization by Stenotrophomonas maltophilia: antimicrobial susceptibility and clinical background of strains isolated at a tertiary care centre in Hungary
title_fullStr Infection and colonization by Stenotrophomonas maltophilia: antimicrobial susceptibility and clinical background of strains isolated at a tertiary care centre in Hungary
title_full_unstemmed Infection and colonization by Stenotrophomonas maltophilia: antimicrobial susceptibility and clinical background of strains isolated at a tertiary care centre in Hungary
title_short Infection and colonization by Stenotrophomonas maltophilia: antimicrobial susceptibility and clinical background of strains isolated at a tertiary care centre in Hungary
title_sort infection and colonization by stenotrophomonas maltophilia: antimicrobial susceptibility and clinical background of strains isolated at a tertiary care centre in hungary
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307884/
https://www.ncbi.nlm.nih.gov/pubmed/25551459
http://dx.doi.org/10.1186/s12941-014-0058-9
work_keys_str_mv AT juhaszemese infectionandcolonizationbystenotrophomonasmaltophiliaantimicrobialsusceptibilityandclinicalbackgroundofstrainsisolatedatatertiarycarecentreinhungary
AT krizsangergely infectionandcolonizationbystenotrophomonasmaltophiliaantimicrobialsusceptibilityandclinicalbackgroundofstrainsisolatedatatertiarycarecentreinhungary
AT lengyelgyorgy infectionandcolonizationbystenotrophomonasmaltophiliaantimicrobialsusceptibilityandclinicalbackgroundofstrainsisolatedatatertiarycarecentreinhungary
AT groszgabor infectionandcolonizationbystenotrophomonasmaltophiliaantimicrobialsusceptibilityandclinicalbackgroundofstrainsisolatedatatertiarycarecentreinhungary
AT pongraczjulia infectionandcolonizationbystenotrophomonasmaltophiliaantimicrobialsusceptibilityandclinicalbackgroundofstrainsisolatedatatertiarycarecentreinhungary
AT kristofkatalin infectionandcolonizationbystenotrophomonasmaltophiliaantimicrobialsusceptibilityandclinicalbackgroundofstrainsisolatedatatertiarycarecentreinhungary